LG Chem’s incrementally modified new diabetes treatment, ‘Zemimet Tab,’ has once again been subject to Price-Volume Agreement negotiations this year and its price will be discounted as of the 1st of next month. This is the fifth price cut made through the PVA system for the drug since its reimbursement approval. Its price had fallen nearly 10% during the period.

According to the industry on the 29th, Zemimet Tab was applied Type C of PVA negotiations, the ceiling price of all four strengths of Zemimet SR Tab were discounted. The discount rate varies by strength but was in the 1.1% to 1.5% range.

This is already the fifth price discount made through the PVA system, indicating the expone